Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Structural reengineering of imatinib to decrease cardiac risk in cancer therapy.

George D Demetri1

  • 1Ludwig Center for Cancer Research, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts 02115, USA. gdemetri@partners.org

The Journal of Clinical Investigation
|December 7, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tazemetostat, an EZH2 inhibitor, in solid tumors harboring SWI/SNF alterations: a phase II basket study.

Nature communications·2026
Same author

Epigenetic dysregulation of metabolic programs mediates liposarcoma cell plasticity.

Science translational medicine·2026
Same author

Epigenetic dysregulation of metabolic programs mediates liposarcoma cell plasticity.

bioRxiv : the preprint server for biology·2025
Same author

Improving Collection and Analysis of Overall Survival Data.

Clinical cancer research : an official journal of the American Association for Cancer Research·2024
Same author

Safety and Efficacy of the Combination Lurbinectedin plus Doxorubicin from a Phase 1b Trial in Patients with Advanced/Metastatic Soft-Tissue Sarcoma.

Clinical cancer research : an official journal of the American Association for Cancer Research·2024
Same author

Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial.

Lancet (London, England)·2024
Same journal

Extracellular matrix reprogramming by the YAP/TAZ- TGF-ß2 axis drives immune exclusion in cholangiocarcinoma models.

The Journal of clinical investigation·2026
Same journal

Tumor cell-derived extracellular vesicles foster the immunosuppressive landscape of pancreatic cancer.

The Journal of clinical investigation·2026
Same journal

Julie Zikherman receives the ASCI/Marian W. Ropes, MD, Award.

The Journal of clinical investigation·2026
Same journal

Targeted degradation of MDM2 overcomes feedback regulation of p53 signaling in Merkel cell carcinoma models.

The Journal of clinical investigation·2026
Same journal

SGLT2 inhibitors enhance ketogenesis by acting as allosteric activators of the mitochondrial enzyme HMGCS2.

The Journal of clinical investigation·2026
Same journal

MDM2 degraders for Merkel cell carcinoma: round peg in a round hole.

The Journal of clinical investigation·2026
See all related articles

Researchers reengineered imatinib to reduce cardiac toxicity. The new compound, WBZ_4, maintains anticancer efficacy against gastrointestinal stromal tumors by inhibiting KIT tyrosine kinase, showing improved safety.

Area of Science:

  • Oncology
  • Pharmacology
  • Drug Discovery

Background:

  • Imatinib is a tyrosine kinase inhibitor effective against certain cancers but poses risks of cardiac toxicity due to ABL kinase inhibition.
  • Developing safer anticancer drugs with similar efficacy is a critical clinical need.

Discussion:

  • Fernández et al. modified imatinib's structure to create WBZ_4, removing ABL kinase inhibition.
  • WBZ_4 retains anticancer activity against gastrointestinal stromal tumors by inhibiting KIT tyrosine kinase.
  • WBZ_4 demonstrates reduced cardiotoxicity compared to imatinib, potentially through JNK inhibition.

Key Insights:

  • Chemical modification of existing drugs can decouple desired efficacy from off-target toxicities.
  • Targeting KIT tyrosine kinase is a viable strategy for gastrointestinal stromal tumor treatment.

Related Experiment Videos

  • Inhibition of JNK may contribute to the improved safety profile of WBZ_4.

    • Outlook:

    • This study validates the feasibility of structural drug reengineering for enhanced tolerability and preserved efficacy.
    • WBZ_4 represents a promising lead compound for developing safer kinase inhibitor therapies.
    • Further clinical investigation is warranted to confirm the safety and efficacy of WBZ_4.